Urinary Complement proteome strongly linked to diabetic kidney disease progression
Zaipul I. Md Dom, Salina Moon, Eiichiro Satake, Daigoro Hirohama, Nicholette D. Allred, Heather C. Lampert, Linda Ficociello, Amin Abedini, Karen S. Fernández, Xiujie Liang, Sara Pickett, Jonathan Levinsohn, Kristina O’Neil, Simon T. Dillon, Michael Mauer, Andrzej T. Gałecki, Barry I. Freedman, Katalin Suszták, Alessandro Doria, Andrzej S. Królewski, Monika A. Niewczas
Abstract
Diabetic kidney disease (DKD) progression is not well understood. Using high-throughput proteomics, biostatistical, pathway and machine learning tools, we examine the urinary Complement proteome in two prospective cohorts with type 1 or 2 diabetes and advanced DKD followed for 1,804 person-years. The top 5% urinary proteins representing multiple components of the Complement system (C2, C5a, CL-K1, C6, CFH and C7) are robustly associated with 10-year kidney failure risk, independent of clinical covariates. We confirm the top proteins in three early-to-moderate DKD cohorts (2,982 person-years). Associations are especially pronounced in advanced kidney disease stages, similar between the two diabetes types and far stronger for urinary than circulating proteins. We also observe increased Complement protein and single cell/spatial RNA expressions in diabetic kidney tissue. Here, our study shows Complement engagement in DKD progression and lays the groundwork for developing biomarker-guided treatments. Complement proteome engagement is strongly linked to kidney outcomes in diabetes. This translational study leveraged five cohorts of over 4,500 person-years and high-throughput proteomics to enable potential biomarker-guided drug development.